Federal Peptide Policy Shift Could Ignite a New Wave Of Growth Across the $164 Billion Peptide Market

This GlobeNewswire item is a paid FN Media promotional roundup built around HHS's October 30, 2026 interim enforcement-discretion policy allowing compounding of six peptides (BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax) by qualifying 503A pharmacies. Altimmune (ALT) is mentioned only in a list of peptide-sector companies positioned to benefit; the substantive news in the release concerns The Precision Peptide Company (PNGAF/BPC), which disclosed $4,600 compensation was paid for the coverage.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.